Brief: Kala Pharmaceuticals Q4 EPS USD -3.18

KALA BIO

29/03/2024 12:00

Mar 29 (Reuters) - Kala Pharmaceuticals Q4 net income USD -8.627 million.
* Q4 operating expenses USD 9.619 million
* Q4 income from operations USD -9.619 million